NasdaqGS:IDYABiotechs
IDEAYA Biosciences (IDYA) Is Up 10.4% After Pivotal Trial Enrollment And GSK Asset Reversion News - Has The Bull Case Changed?
In recent days, UBS initiated coverage on IDEAYA Biosciences and the company reported full enrollment of its pivotal Phase 2/3 darovasertib trial in metastatic uveal melanoma, while GlaxoSmithKline opted to end their collaboration and return the Werner Helicase and Pol Theta programs by March 2026.
This combination of fresh analyst attention, approaching pivotal data, and regained control of key oncology assets reshapes how investors may view IDEAYA’s pipeline breadth and future...